Cargando…
Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study
INTRODUCTION: Chimeric antigen receptor T-cell (CAR T) therapy offers a potentially curative option for patients with relapsed and refractory hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Patient-reported experiences with CAR T therapy are limited and have not been well...
Autores principales: | Cheng, Rebecca, Scippa, Kayla, Locke, Frederick L., Snider, Julia Thornton, Jim, Heather |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590924/ https://www.ncbi.nlm.nih.gov/pubmed/34778941 http://dx.doi.org/10.1007/s40487-021-00174-0 |
Ejemplares similares
-
Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
por: Sheikh, Semira, et al.
Publicado: (2021) -
CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019) -
CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma
por: Quintás-Cardama, Alfonso
Publicado: (2018) -
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022) -
Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)